



SightGlass Vision Names Natalia Trela-McDonald as Head of Research and Development

*Trela-McDonald Brings Over a Decade of Experience in Engineering and Physics,
Paired With a Personal Motivation for Myopia Management*

DALLAS, November 20, 2025—SightGlass Vision has appointed Natalia Trela-McDonald as Senior Director of R&D and Technology, bringing a wealth of experience in optical device design and commercialization to its leadership team. In her new role, Trela-McDonald is advancing the company's work in contrast management and leading the development of next-generation lens designs and materials to further enhance the proven efficacy and performance of its DOT™ myopia control spectacle lenses.

Trela-McDonald spent nearly 14 years at PowerPhotonic, spearheading product development and overseeing the company's U.K. business in advanced optical components for laser systems in medical devices, defense technologies, and industrial applications. She earned her master's degree in Electronics and Telecommunication from Wrocław University of Science and Technology and her doctorate in Physics from Heriot-Watt University in Edinburgh, Scotland.

"Having experienced myopia myself, I understand the importance of early intervention," said Trela-McDonald. "As both a scientist and a parent of young children, I'm inspired by SightGlass Vision's mission to give every child access to this technology that can truly change the course of their eye health for the future. My goal is to build on the company's already strong foundation to make DOT lenses even more effective and accessible, so that as many children as possible can benefit from them."

DOT spectacle lenses are the first device designed to both correct vision and slow myopia progression by mimicking more natural contrast.^{1,2,3} To do this, the lenses include thousands of elements that softly scatter light before it hits the retina.⁴ DOT lenses offer unsurpassed visual acuity in the treatment zone and sharp all-around vision.⁵ After 12 months of wear, DOT lenses have been shown to slow myopia progression by up to 75% across diverse populations.*^{6,7}

“Natalia’s passion for safeguarding children’s vision and her expert knowledge in optical technologies equip her wonderfully to head R&D at SightGlass Vision,” said Andrew Sedgwick, CEO of SightGlass Vision. “Alongside our team of ocular scientists, her leadership will be instrumental in our mission to bring effective myopia control to children around the world.”

SightGlass Vision’s patent-protected DOT lenses have made their commercial debut in several markets, including China, Israel, Canada, Spain, and the U.K., with over one million children having already worn the lenses.†,‡ Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International.

For more information, visit SightGlassVision.com.

###

About SightGlass Vision

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

*** Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Lenses were worn 10 hours per day.**

† *This figure is based on sales data and reflects global usage across multiple regions.*

‡ *SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.*

Media Contact

Carson Daniels, Senior Counselor

McDougall Communications for SightGlass Vision

+1-315-427-6394 or carson@mcdougallpr.com

1. **Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023;107(11):1709–1715.**
2. **Laughton D, et al. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS): BMJ Open Ophthalmology 2024;9:e001790;**
3. **Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2815.**
4. **Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol 2023;107:1709-1715.1.**
5. **Rani et al. Treatment zone visual acuity with myopia control spectacle lenses. ARVO 2024 presentation.**
6. **Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol. 2023;107:1709-1715**
7. **Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2815.**